Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison

被引：6
作者：
Ishak, K. Jack [1 ]
Rael, Michael [2 ]
Hicks, Meagen [3 ]
Mittal, Sangeeta [3 ]
Eatock, Martin [4 ]
Valle, Juan W. [5 ,6 ]
机构：
[1] Evidera Inc, Montreal, PQ, Canada
[2] Evidera Inc, San Francisco, CA 94111 USA
[3] Pfizer Ltd, Walton Oaks, Surrey, England
[4] Belfast City Hosp, Northern Ireland Canc Ctr, Belfast, Antrim, North Ireland
[5] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England
[6] Christie NHS Fdn Trust, Manchester, Lancs, England
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 10期
关键词：
comparative effectiveness; everolimus; MAIC; matching-adjusted indirect comparison; sunitinib;
D O I：
10.2217/cer-2018-0020
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111). Methods: The MAIC matched on all baseline characteristics available from both studies. An anchored MAIC was performed for progression-free survival (PFS); an unanchored analysis was deemed more appropriate for OS due to crossover in both trials. A hazard ratio for sunitinib versus everolimus was derived from adjusted (weighted) sunitinib effects compared with the observed results for everolimus. Results: The adjusted hazard ratio for sunitinib versus everolimus was 0.85 (0.39-1.89) for PFS and 0.82 (0.53-1.27) for OS. Conclusion: Findings indicate comparable PFS and OS with sunitinib and everolimus.
引用
收藏
页码：947 / 958
页数：12
相关论文
共 50 条
  • [41] Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life
    Agirrezabal, Ion
    Brennan, Victoria K.
    Colaone, Fabien
    Shergill, Suki
    Pereira, Helena
    Chatellier, Gilles
    Vilgrain, Valerie
    ADVANCES IN THERAPY, 2022, 39 (05) : 2035 - 2051
  • [42] Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons
    Paul, Damemarie
    Swallow, Elyse
    Patterson-Lomba, Oscar
    Branchcomb, Tychell
    N'Dri, Laetitia
    Gomez-Lievano, Andres
    Liu, Jingyi
    Dua, Akanksha
    Mcginley, Marisa
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [43] An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed
    Sherman, Steven
    Amzal, Billy
    Calvo, Emiliano
    Wang, Xufang
    Park, Jinhee
    Liu, Zhimei
    Lin, Chinjune
    Casciano, Roman
    CLINICAL THERAPEUTICS, 2015, 37 (11) : 2552 - 2559
  • [44] A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini, A. A.
    Toor, K.
    Chan, K.
    McDermott, D. F.
    Mohr, P.
    Larkin, J.
    Hodi, F. S.
    Lee, C-H
    Rizzo, J., I
    Johnson, H.
    Moshyk, A.
    Rao, S.
    Kotapati, S.
    Atkins, M. B.
    ESMO OPEN, 2021, 6 (02)
  • [45] Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
    Bonanad, Santiago
    Nunez, Ramiro
    Luis Poveda, Jose
    Kurnik, Karin
    Goldmann, Georg
    Andreozzi, Valeska
    Vandewalle, Bjorn
    Santos, Sandra
    ADVANCES IN THERAPY, 2021, 38 (09) : 4872 - 4884
  • [46] Pembrolizumab plus chemotherapy versus atezolizumab plus chemotherapy plus /-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    LUNG CANCER, 2021, 155 : 175 - 182
  • [47] Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
    Santiago Bonanad
    Ramiro Núñez
    Jose Luis Poveda
    Karin Kurnik
    Georg Goldmann
    Valeska Andreozzi
    Björn Vandewalle
    Sandra Santos
    Advances in Therapy, 2021, 38 : 4872 - 4884
  • [48] Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
    Maloney, David G.
    Kuruvilla, John
    Liu, Fei Fei
    Kostic, Ana
    Kim, Yeonhee
    Bonner, Ashley
    Zhang, Yixie
    Fox, Christopher P.
    Cartron, Guillaume
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [49] Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
    David G. Maloney
    John Kuruvilla
    Fei Fei Liu
    Ana Kostic
    Yeonhee Kim
    Ashley Bonner
    Yixie Zhang
    Christopher P. Fox
    Guillaume Cartron
    Journal of Hematology & Oncology, 14
  • [50] 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (12) : 1195 - 1203
12345